Glutamate Receptor Ionotropic NMDA 2B (NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Pipeline Review, H1 2016

Description: Glutamate Receptor Ionotropic NMDA 2B (NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Pipeline Review, H1 2016

Summary

‘Glutamate Receptor Ionotropic NMDA 2B (NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Pipeline Review, H1 2016’, provides in depth analysis on Glutamate Receptor Ionotropic NMDA 2B (NMDA Receptor Subunit Epsilon 2 or GRIN2B) targeted pipeline therapeutics.

The report provides comprehensive information on the Glutamate Receptor Ionotropic NMDA 2B (NMDA Receptor Subunit Epsilon 2 or GRIN2B) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glutamate Receptor Ionotropic NMDA 2B (NMDA Receptor Subunit Epsilon 2 or GRIN2B) targeted therapeutics development and features dormant and discontinued projects.

The author’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Glutamate Receptor Ionotropic NMDA 2B (NMDA Receptor Subunit Epsilon 2 or GRIN2B)
- The report reviews Glutamate Receptor Ionotropic NMDA 2B (NMDA Receptor Subunit Epsilon 2 or GRIN2B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Glutamate Receptor Ionotropic NMDA 2B (NMDA Receptor Subunit Epsilon 2 or GRIN2B) targeted therapeutics and enlists all their major and minor projects
- The report assesses Glutamate Receptor Ionotropic NMDA 2B (NMDA Receptor Subunit Epsilon 2 or GRIN2B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Glutamate Receptor Ionotropic NMDA 2B (NMDA Receptor Subunit Epsilon 2 or GRIN2B) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D
strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Glutamate Receptor Ionotropic NMDA 2B (NMDA Receptor Subunit Epsilon 2 or GRIN2B)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glutamate Receptor Ionotropic NMDA 2B (NMDA Receptor Subunit Epsilon 2 or GRIN2B) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents:
List of Tables
List of Figures
Introduction
Report Coverage
Glutamate Receptor Ionotropic NMDA 2B (NMDA Receptor Subunit Epsilon 2 or GRIN2B) Overview
Therapeutics Development
Glutamate Receptor Ionotropic NMDA 2B (NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Products under Development by Stage of Development
Glutamate Receptor Ionotropic NMDA 2B (NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Products under Development by Therapy Area
Glutamate Receptor Ionotropic NMDA 2B (NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Products under Development by Indication
Glutamate Receptor Ionotropic NMDA 2B (NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Glutamate Receptor Ionotropic NMDA 2B (NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Products under Development by Companies
Glutamate Receptor Ionotropic NMDA 2B (NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Glutamate Receptor Ionotropic NMDA 2B (NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Companies Involved in Therapeutics Development
BioCrea GmbH
Bristol-Myers Squibb Company
Cerecor Inc.
Johnson & Johnson
Luc Therapeutics, Inc.
NeurOp, Inc
Novartis AG
UCB S.A.

Glutamate Receptor Ionotropic NMDA 2B (NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Drug Profiles

CERC-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

EVT-100 Series - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

EVT-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

NP-10679 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

NP-11948 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

radiprodil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize NMDA2B for Cognitive Impairment Associated With Schizophrenia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize NMDA Receptor 2B for Depression and Major Depressive Disorder - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize NR2B for Depression - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize NR2B for Neuropathic Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Glutamate Receptor Ionotropic NMDA 2B (NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Dormant Projects

Glutamate Receptor Ionotropic NMDA 2B (NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Discontinued Products

Glutamate Receptor Ionotropic NMDA 2B (NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Featured News & Press Releases

Jan 19, 2016: Cerecor Announces Publication Describing Antidepressant Activity of CERC-301 in Preclinical Model

Sep 03, 2015: Cerecor Initiates Phase 2 Study for CERC-301, an Antidepressant Product Candidate with Potential for Rapid Onset of Effect

Mar 20, 2015: Cerecor Provides Update on CERC-301 Development in Major Depressive Disorder

Oct 03, 2014: Cerecor to Present at 13th Annual BIO Investor Forum

Oct 02, 2014: NeurOp Receives Milestone Payment as Bristol-Myers Squibb Nominates NMDA Receptor Compound as Drug Development Candidate

Dec 02, 2013: MedAvante Central Ratings Selected For Cerecor Investigational MDD Study

Nov 25, 2013: Cerecor Receives Fast Track Designation for CERC-301 for the Treatment of Major Depressive Disorder

Nov 08, 2013: Cerecor Announces Initiation of Phase 2 Study for CERC-301, an Oral Rapid-acting Antidepressant Candidate
Jun 28, 2010: Forest And Gedeon Richter Announce Phase II Study Results Of Radiprodil For Treatment Of Diabetic Peripheral Neuropathic Pain

Mar 11, 2010: Evotec Completes Clinical Part Of First Phase I Study Of EVT 103

Sep 08, 2009: Evotec Starts Phase I With EVT 103, An NR2B-Selective NMDA Receptor Antagonist

Nov 29, 2005: Gedeon Richter And Forest Laboratories Expand Relationship With Two New Collaborations For CNS Compounds

Mar 24, 2004: Evotec Neurosciences License NMDA Receptor NR2B Subunit Selective Antagonists From Roche

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 52List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by BioCrea GmbH, H1 2016

Pipeline by Bristol-Myers Squibb Company, H1 2016

Pipeline by Cerecor Inc., H1 2016

Pipeline by Johnson & Johnson, H1 2016

Pipeline by Luc Therapeutics, Inc., H1 2016

Pipeline by NeurOp, Inc, H1 2016
Pipeline by Novartis AG, H1 2016
Pipeline by UCB S.A., H1 2016
Dormant Projects, H1 2016
Discontinued Products, H1 2016

List of Figures
Number of Products under Development for, H1 2016
Number of Products under Development by Indication, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Mechanism of Actions, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3802773/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Glutamate Receptor Ionotropic NMDA 2B (NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Pipeline Review, H1 2016
Web Address: http://www.researchandmarkets.com/reports/3802773/
Office Code: SCH3FXDV

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic - Single User</td>
<td>✔️</td>
<td>USD 3500</td>
</tr>
<tr>
<td>Electronic - Site License</td>
<td>✔️</td>
<td>USD 7000</td>
</tr>
<tr>
<td>Electronic - EnterpriseWide</td>
<td>✔️</td>
<td>USD 10500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: __________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World